China strengthens Anti-Foreign Sanctions Law in response to U.S. restrictions; Chinese firms move production facilities overseas amidst key economic changes; and China introduces regulations to protect interests in overseas IP disputes
A compliance audit is required when processing personal information of more than 10 million persons / CLP Reference: 5600/25.02.12 ; Promulgated: 2025-02-12 ; Effective: 2025-05-01
Multinationals must comply with new Chinese labeling requirements while the U.S. and EU have other specifications; A second Chinese court ruling affirms AI-generated images have copyright protection; and Supreme People’s Court cracks down on fraudulent behavior of prepayment service providers
Hotel rooms and restaurants are prohibited from installing image capturing equipment / CLP Reference: 5600/25.01.13 ; Promulgated: 2025-01-13 ; Effective: 2025-04-01
Hong Kong stock market rebounds when Chinese government halts Swiss listings; China backs AI with government investment fund; and China’s Supreme People’s Court further protects intellectual property rights in apple plant varieties.
China clamps down on small-cap U.S. listings by Chinese issuers; China mandates personal information protection compliance audits for companies; and AI company loses against Reuters in U.S. summary judgment with key implication
Philip Qu of TransAsia Lawyers analyze regulatory and statutory progress in China’s ever flourishing TMT sector in 2024, and look at the outlook for 2025
Trump signs memorandum to restrict investments that do not serve American interests; A Jiangsu court ruled that investments in overseas crypto projects are not protected under Chinese law; and Chinese companies raise funds in hope of easing of regulations against private enterprises
2024 marked another significant year in China’s intellectual property law space. Danlei Wu of Fangda Partners examines the key developments and the indicators for further developments in the year ahead
Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
